Advertisement
Screener

CRISPR THERAPEUTICS AG (CRSP) Depreciation

2.8 / 5 stars · 68/120 Roast Me

CRISPR THERAPEUTICS AG Depreciation

CRISPR THERAPEUTICS AG (CRSP) reported Depreciation of $4.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Cash Flow › Operating Activities

us-gaap:Depreciation · last filed 2026-08-03

  • CRISPR THERAPEUTICS AG depreciation for the quarter ending 2026-06-30 was $4.30M, a 6.52% decline year-over-year.
  • CRISPR THERAPEUTICS AG depreciation for the quarter ending 2026-03-31 was $4.30M, a 8.51% decline year-over-year.
  • CRISPR THERAPEUTICS AG depreciation for the quarter ending 2025-12-31 was $5.60M, a 16.67% increase year-over-year.
  • CRISPR THERAPEUTICS AG depreciation for the quarter ending 2025-09-30 was $4.40M, a 8.33% decline year-over-year.
  • CRISPR THERAPEUTICS AG depreciation for fiscal 2025 was $19.40M, a 1.04% increase from fiscal 2024.
  • CRISPR THERAPEUTICS AG depreciation for fiscal 2024 was $19.20M, a 3.03% decline from fiscal 2023.
  • CRISPR THERAPEUTICS AG depreciation for fiscal 2023 was $19.80M, a 17.84% decline from fiscal 2022.
  • CRISPR THERAPEUTICS AG depreciation for fiscal 2022 was $24.10M, a 34.64% increase from fiscal 2021.
Period endDepreciation 3 monthDepreciation 6 monthDepreciation 9 monthDepreciation 9 month as first filedDepreciation 12 month
2026-06-30$4.30M
10-Q · filed 2026-08-03
$8.60M
10-Q · filed 2026-08-03
$14.20M
derived: sum of 3 quarters · filed 2026-08-03
$18.60M
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31$4.30M
10-Q · filed 2026-05-04
$9.90M
derived: sum of 2 quarters · filed 2026-05-04
$14.30M
derived: sum of 3 quarters · filed 2026-05-04
$18.90M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31$5.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12
$10.00M
derived: sum of 2 quarters · filed 2026-02-12
$14.60M
derived: sum of 3 quarters · filed 2026-08-03
$19.40M
10-K · filed 2026-02-12
2025-09-30$4.40M
10-Q · filed 2025-11-10
$9.00M
derived: sum of 2 quarters · filed 2026-08-03
$13.80M
10-Q · filed 2025-11-10
$18.50M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30$4.60M
10-Q · filed 2026-08-03
$9.30M
10-Q · filed 2026-08-03
$14.10M
derived: sum of 3 quarters · filed 2026-08-03
$18.90M
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31$4.70M
10-Q · filed 2026-05-04
$9.50M
derived: sum of 2 quarters · filed 2026-05-04
$14.30M
derived: sum of 3 quarters · filed 2026-05-04
$19.10M
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31$4.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12
$9.60M
derived: sum of 2 quarters · filed 2026-02-12
$14.40M
derived: sum of 3 quarters · filed 2026-02-12
$19.20M
10-K · filed 2026-02-12
2024-09-30$4.80M
10-Q · filed 2025-11-10
$9.60M
derived: sum of 2 quarters · filed 2025-11-10
$14.40M
10-Q · filed 2025-11-10
$19.30M
derived: sum of 4 quarters · filed 2026-02-12
2024-06-30$4.80M
10-Q · filed 2025-08-04
$9.60M
10-Q · filed 2025-08-04
$14.50M
derived: sum of 3 quarters · filed 2026-02-12
$19.40M
derived: sum of 4 quarters · filed 2026-02-12
2024-03-31$4.80M
10-Q · filed 2025-05-06
$9.70M
derived: sum of 2 quarters · filed 2026-02-12
$14.60M
derived: sum of 3 quarters · filed 2026-02-12
$19.60M
derived: sum of 4 quarters · filed 2026-02-12
2023-12-31$4.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12
$9.80M
derived: sum of 2 quarters · filed 2026-02-12
$14.80M
derived: sum of 3 quarters · filed 2026-02-12
$19.80M
10-K · filed 2026-02-12
2023-09-30$4.90M
10-Q · filed 2024-11-05
$9.90M
derived: sum of 2 quarters · filed 2024-11-05
$14.90M
10-Q · filed 2024-11-05
$20.70M
derived: sum of 4 quarters · filed 2025-02-11
2023-06-30$5.00M
10-Q · filed 2024-08-05
$10.00M
10-Q · filed 2024-08-05
$15.80M
derived: sum of 3 quarters · filed 2025-02-11
$20.80M
derived: sum of 4 quarters · filed 2025-02-11
2023-03-31$5.00M
10-Q · filed 2024-05-08
$10.80M
derived: sum of 2 quarters · filed 2025-02-11
$15.80M
derived: sum of 3 quarters · filed 2025-02-11
$23.10M
derived: sum of 4 quarters · filed 2025-02-11
2022-12-31$5.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11
$10.80M
derived: sum of 2 quarters · filed 2025-02-11
$18.10M
derived: sum of 3 quarters · filed 2025-02-11
$24.10M
10-K · filed 2025-02-11
2022-09-30$5.00M
10-Q · filed 2023-11-06
$12.30M
derived: sum of 2 quarters · filed 2023-11-06
$18.30M
10-Q · filed 2023-11-06
$24.50M
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30$7.30M
10-Q · filed 2023-08-07
$13.30M
10-Q · filed 2023-08-07
$19.50M
derived: sum of 3 quarters · filed 2024-02-21
$24.80M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31$6.00M
10-Q · filed 2023-05-08
$12.20M
derived: sum of 2 quarters · filed 2024-02-21
$17.50M
derived: sum of 3 quarters · filed 2024-02-21
$21.10M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31$6.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
$11.50M
derived: sum of 2 quarters · filed 2024-02-21
$15.10M
derived: sum of 3 quarters · filed 2024-02-21
$17.90M
10-K · filed 2024-02-21
2021-09-30$5.30M
10-Q · filed 2022-11-01
$8.90M
derived: sum of 2 quarters · filed 2022-11-01
$11.70M
10-Q · filed 2022-11-01
$14.10M
derived: sum of 4 quarters · filed 2023-02-21
2021-06-30$3.60M
10-Q · filed 2022-08-08
$6.30M
10-Q · filed 2022-08-08
$8.80M
derived: sum of 3 quarters · filed 2023-02-21
$11.10M
derived: sum of 4 quarters · filed 2023-02-21
2021-03-31$2.70M
10-Q · filed 2022-05-09
$5.20M
derived: sum of 2 quarters · filed 2023-02-21
$7.50M
derived: sum of 3 quarters · filed 2023-02-21
$9.70M
derived: sum of 4 quarters · filed 2023-02-21
2020-12-31$2.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21
$4.80M
derived: sum of 2 quarters · filed 2023-02-21
$7.00M
derived: sum of 3 quarters · filed 2023-02-21
$9.10M
10-K · filed 2023-02-21
2020-09-30$2.30M
10-Q · filed 2021-11-03
$4.50M
derived: sum of 2 quarters · filed 2021-11-03
$6.60M
10-Q · filed 2021-11-03
$8.00M
derived: sum of 4 quarters · filed 2022-02-15
2020-06-30$2.20M
10-Q · filed 2021-07-29
$4.30M
10-Q · filed 2021-07-29
$5.70M
derived: sum of 3 quarters · filed 2022-02-15
$7.00M
derived: sum of 4 quarters · filed 2022-02-15
2020-03-31$2.10M
10-Q · filed 2021-04-27
$3.50M
derived: sum of 2 quarters · filed 2022-02-15
$4.80M
derived: sum of 3 quarters · filed 2022-02-15
$5.80M
derived: sum of 4 quarters · filed 2022-02-15
2019-12-31$1.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15
$2.70M
derived: sum of 2 quarters · filed 2022-02-15
$3.70M
derived: sum of 3 quarters · filed 2022-02-15
$4.70M
10-K · filed 2022-02-15
2019-09-30$1.30M
10-Q · filed 2020-10-28
$2.30M
derived: sum of 2 quarters · filed 2020-10-28
$3.30M
10-Q · filed 2020-10-28
$4.20M
derived: sum of 4 quarters · filed 2021-02-16
2019-06-30$1.00M
10-Q · filed 2020-07-27
$2.00M
10-Q · filed 2020-07-27
$2.90M
derived: sum of 3 quarters · filed 2021-02-16
$3.70M
derived: sum of 4 quarters · filed 2021-02-16
2019-03-31$1.00M
10-Q · filed 2020-04-28
$1.90M
derived: sum of 2 quarters · filed 2021-02-16
$2.70M
derived: sum of 3 quarters · filed 2021-02-16
$3.60M
derived: sum of 4 quarters · filed 2021-02-16
2018-12-31$900.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16
$1.70M
derived: sum of 2 quarters · filed 2021-02-16
$2.60M
derived: sum of 3 quarters · filed 2021-02-16
$3.50M
10-K · filed 2021-02-16
2018-09-30$800.00K
10-Q · filed 2019-10-28
$1.70M
derived: sum of 2 quarters · filed 2019-10-28
$2.60M
10-Q · filed 2019-10-28
$2.50M
10-Q · filed 2018-11-07
$3.30M
derived: sum of 4 quarters · filed 2020-02-12
2018-06-30$900.00K
10-Q · filed 2019-07-29
$1.70M
10-Q · filed 2019-07-29
$2.50M
derived: sum of 3 quarters · filed 2020-02-12
$3.30M
derived: sum of 4 quarters · filed 2020-02-12
2018-03-31$800.00K
10-Q · filed 2019-04-29
$1.60M
derived: sum of 2 quarters · filed 2020-02-12
$2.40M
derived: sum of 3 quarters · filed 2020-02-12
$3.10M
derived: sum of 4 quarters · filed 2020-02-12
2017-12-31$800.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12
$1.60M
derived: sum of 2 quarters · filed 2020-02-12
$2.30M
derived: sum of 3 quarters · filed 2020-02-12
$3.00M
10-K · filed 2020-02-12
2017-09-30$800.00K
10-Q · filed 2018-11-07
$1.50M
derived: sum of 2 quarters · filed 2018-11-07
$2.20M
10-Q · filed 2018-11-07
$2.60M
derived: sum of 4 quarters · filed 2019-02-25
2017-06-30$700.00K
10-Q · filed 2018-08-07
$1.40M
10-Q · filed 2018-08-07
$1.80M
derived: sum of 3 quarters · filed 2019-02-25
$2.00M
derived: sum of 4 quarters · filed 2019-02-25
2017-03-31$700.00K
10-Q · filed 2018-05-08
$1.10M
derived: sum of 2 quarters · filed 2019-02-25
$1.30M
derived: sum of 3 quarters · filed 2019-02-25
$1.40M
derived: sum of 4 quarters · filed 2019-02-25
2016-12-31$400.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25
$600.00K
derived: sum of 2 quarters · filed 2019-02-25
$700.00K
derived: sum of 3 quarters · filed 2019-02-25
$900.00K
10-K · filed 2019-02-25
2016-09-30$200.00K
10-Q · filed 2017-11-08
$300.00K
derived: sum of 2 quarters · filed 2017-11-08
$500.00K
10-Q · filed 2017-11-08
$473.00K
derived: sum of 4 quarters · filed 2018-03-08
2016-06-30$100.00K
10-Q · filed 2017-08-10
$200.00K
10-Q · filed 2017-08-10
$273.00K
derived: sum of 3 quarters · filed 2018-03-08
$300.00K
derived: sum of 4 quarters · filed 2018-03-08
2016-03-31$100.00K
10-Q · filed 2017-05-11
$173.00K
derived: sum of 2 quarters · filed 2018-03-08
$200.00K
derived: sum of 3 quarters · filed 2018-03-08
2015-12-31$73.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$100.00K
derived: sum of 2 quarters · filed 2018-03-08
$100.00K
10-K · filed 2018-03-08
2015-09-30$27.00K
10-Q · filed 2016-11-22
$27.00K
10-Q · filed 2016-11-22
2014-12-31$0.00
10-K · filed 2017-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B